199 related articles for article (PubMed ID: 19246643)
1. Oxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic Ren2 rats.
Wei Y; Clark SE; Thyfault JP; Uptergrove GM; Li W; Whaley-Connell AT; Ferrario CM; Sowers JR; Ibdah JA
Am J Pathol; 2009 Apr; 174(4):1329-37. PubMed ID: 19246643
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats.
Wei Y; Clark SE; Morris EM; Thyfault JP; Uptergrove GM; Whaley-Connell AT; Ferrario CM; Sowers JR; Ibdah JA
J Hepatol; 2008 Sep; 49(3):417-28. PubMed ID: 18486983
[TBL] [Abstract][Full Text] [Related]
3. Angiotensin II-mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2) 27 Ren2 rat.
Whaley-Connell A; Govindarajan G; Habibi J; Hayden MR; Cooper SA; Wei Y; Ma L; Qazi M; Link D; Karuparthi PR; Stump C; Ferrario C; Sowers JR
Am J Physiol Endocrinol Metab; 2007 Jul; 293(1):E355-63. PubMed ID: 17440033
[TBL] [Abstract][Full Text] [Related]
4. Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression.
Blendea MC; Jacobs D; Stump CS; McFarlane SI; Ogrin C; Bahtyiar G; Stas S; Kumar P; Sha Q; Ferrario CM; Sowers JR
Am J Physiol Endocrinol Metab; 2005 Feb; 288(2):E353-9. PubMed ID: 15494608
[TBL] [Abstract][Full Text] [Related]
5. NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat.
Wei Y; Whaley-Connell AT; Chen K; Habibi J; Uptergrove GM; Clark SE; Stump CS; Ferrario CM; Sowers JR
Hypertension; 2007 Aug; 50(2):384-91. PubMed ID: 17533199
[TBL] [Abstract][Full Text] [Related]
6. Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat.
Whaley-Connell AT; Chowdhury NA; Hayden MR; Stump CS; Habibi J; Wiedmeyer CE; Gallagher PE; Tallant EA; Cooper SA; Link CD; Ferrario C; Sowers JR
Am J Physiol Renal Physiol; 2006 Dec; 291(6):F1308-14. PubMed ID: 16788142
[TBL] [Abstract][Full Text] [Related]
7. Metabolomics in angiotensin II-induced cardiac hypertrophy.
Mervaala E; Biala A; Merasto S; Lempiäinen J; Mattila I; Martonen E; Eriksson O; Louhelainen M; Finckenberg P; Kaheinen P; Muller DN; Luft FC; Lapatto R; Oresic M
Hypertension; 2010 Feb; 55(2):508-15. PubMed ID: 20065148
[TBL] [Abstract][Full Text] [Related]
8. Oxidative stress contributes to pulmonary hypertension in the transgenic (mRen2)27 rat.
DeMarco VG; Habibi J; Whaley-Connell AT; Schneider RI; Heller RL; Bosanquet JP; Hayden MR; Delcour K; Cooper SA; Andresen BT; Sowers JR; Dellsperger KC
Am J Physiol Heart Circ Physiol; 2008 Jun; 294(6):H2659-68. PubMed ID: 18424632
[TBL] [Abstract][Full Text] [Related]
9. Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat.
Whaley-Connell A; Habibi J; Nistala R; Hayden MR; Pulakat L; Sinak C; Locher B; Ferrario CM; Sowers JR
Regul Pept; 2012 Jun; 176(1-3):36-44. PubMed ID: 22465166
[TBL] [Abstract][Full Text] [Related]
10. Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat.
Whaley-Connell A; Habibi J; Cooper SA; Demarco VG; Hayden MR; Stump CS; Link D; Ferrario CM; Sowers JR
Am J Physiol Endocrinol Metab; 2008 Jul; 295(1):E103-9. PubMed ID: 18460596
[TBL] [Abstract][Full Text] [Related]
11. Loss of biphasic effect on Na/K-ATPase activity by angiotensin II involves defective angiotensin type 1 receptor-nitric oxide signaling.
Banday AA; Lokhandwala MF
Hypertension; 2008 Dec; 52(6):1099-105. PubMed ID: 18955661
[TBL] [Abstract][Full Text] [Related]
12. Salt loading exacerbates diastolic dysfunction and cardiac remodeling in young female Ren2 rats.
Whaley-Connell AT; Habibi J; Aroor A; Ma L; Hayden MR; Ferrario CM; Demarco VG; Sowers JR
Metabolism; 2013 Dec; 62(12):1761-71. PubMed ID: 24075738
[TBL] [Abstract][Full Text] [Related]
13. Proximal tubule microvilli remodeling and albuminuria in the Ren2 transgenic rat.
Hayden MR; Chowdhury NA; Cooper SA; Whaley-Connell A; Habibi J; Witte L; Wiedmeyer C; Manrique CM; Lastra G; Ferrario C; Stump C; Sowers JR
Am J Physiol Renal Physiol; 2007 Feb; 292(2):F861-7. PubMed ID: 17032939
[TBL] [Abstract][Full Text] [Related]
14. Comparative beneficial effects of nebivolol and nebivolol/valsartan combination against mitochondrial dysfunction in angiotensin II-induced pathology in H9c2 cardiomyoblasts.
Gul R; Alsalman N; Bazighifan A; Alfadda AA
J Pharm Pharmacol; 2021 Oct; 73(11):1520-1529. PubMed ID: 34453839
[TBL] [Abstract][Full Text] [Related]
15. Role of angiotensin II and reactive oxygen species in cyclosporine A-dependent hypertension.
Nishiyama A; Kobori H; Fukui T; Zhang GX; Yao L; Rahman M; Hitomi H; Kiyomoto H; Shokoji T; Kimura S; Kohno M; Abe Y
Hypertension; 2003 Oct; 42(4):754-60. PubMed ID: 12874088
[TBL] [Abstract][Full Text] [Related]
16. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease.
Kohjima M; Enjoji M; Higuchi N; Kato M; Kotoh K; Yoshimoto T; Fujino T; Yada M; Yada R; Harada N; Takayanagi R; Nakamuta M
Int J Mol Med; 2007 Sep; 20(3):351-8. PubMed ID: 17671740
[TBL] [Abstract][Full Text] [Related]
17. Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat.
Whaley-Connell A; Nistala R; Habibi J; Hayden MR; Schneider RI; Johnson MS; Tilmon R; Rehmer N; Ferrario CM; Sowers JR
Am J Physiol Renal Physiol; 2010 Mar; 298(3):F655-61. PubMed ID: 20007350
[TBL] [Abstract][Full Text] [Related]
18. Synergistic actions of enalapril and tempol during chronic angiotensin II-induced hypertension.
Elmarakby AA; Williams JM; Imig JD; Pollock JS; Pollock DM
Vascul Pharmacol; 2007 Feb; 46(2):144-51. PubMed ID: 17112788
[TBL] [Abstract][Full Text] [Related]
19. Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease.
Assy N; Grozovski M; Bersudsky I; Szvalb S; Hussein O
World J Gastroenterol; 2006 Jul; 12(27):4369-76. PubMed ID: 16865780
[TBL] [Abstract][Full Text] [Related]
20. Telmisartan but not valsartan increases caloric expenditure and protects against weight gain and hepatic steatosis.
Sugimoto K; Qi NR; Kazdová L; Pravenec M; Ogihara T; Kurtz TW
Hypertension; 2006 May; 47(5):1003-9. PubMed ID: 16567593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
